- Conditions
- Crohn's Disease
- Interventions
- ABBV-8736, Lutikizumab, Risankizumab, Trosunilimab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 590 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 64
- States / cities
- Dothan, Alabama • Mobile, Alabama • Coronado, California + 56 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 1,186
matching trials from the local directory fallback.
- Conditions
- Hepatobiliary Cancers
- Interventions
- Durvalumab-based combination therapies in observational study setting, Durvalumab-based combination therapies in observational study settings, Non Durvalumab-based therapies in observational study setting
- Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 4,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 21 more
- Conditions
- Autism Spectrum Disorder, Bipolar Disorder, Schizophrenia
- Interventions
- Lumateperone
- Drug
- Lead sponsor
- Intra-Cellular Therapies, Inc.
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 59
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 43 more
- Conditions
- Renal Insufficiency, Chronic
- Interventions
- Balcinrenone/dapagliflozin, Dapagliflozin, Placebo matching Dapagliflozin, Placebo matching balcinrenone/dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 2,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 68
- States / cities
- Huntsville, Alabama • Surprise, Arizona • Tempe, Arizona + 63 more
- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
- Interventions
- Aflibercept, Ixo-vec
- Drug · Genetic
- Lead sponsor
- Adverum Biotechnologies, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 534 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 79
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 65 more
- Conditions
- Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
- Interventions
- Muvalaplin, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10,450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 159
- States / cities
- Birmingham, Alabama • Apache Junction, Arizona • Gilbert, Arizona + 129 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Vamorolone
- Drug
- Lead sponsor
- Catalyst Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Years and older · Male only
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 27 more
- Conditions
- Polymyositis, Dermatomyositis
- Interventions
- Anifrolumab (blinded), Anifrolumab (unblinded, open label), Placebo
- Combination Product · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 43
- States / cities
- Phoenix, Arizona • Irvine, California • Aurora, Colorado + 38 more
- Conditions
- Pediatric Migraine
- Interventions
- Matching placebo, Rimegepant/BHV3000
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 2,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 169
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tempe, Arizona + 107 more
- Conditions
- Healthy Subjects, Subjective Cognitive Decline (SCD)
- Interventions
- Control - 1Hz Visual Occlusion, Experimental -- 16.67 Hz Visual Occlusion
- Behavioral
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 65 Years to 89 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Crohn's Disease
- Interventions
- Duvakitug, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 980 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 125
- States / cities
- Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 105 more
- Conditions
- Aneurysmal Subarachnoid Hemorrhage, Delayed Cerebral Ischemia
- Interventions
- tocilizumab-aazg (TYENNE)
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Non-squamous Non-small Cell Lung Cancer
- Interventions
- Carboplatin, Cisplatin, Pembrolizumab, Pemetrexed, Rilvegostomig
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 78
- States / cities
- Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 72 more
- Conditions
- Recurrent Glioblastoma
- Interventions
- NeuroBlate®, Optune GIO®, Pembrolizumab
- Device · Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Multiple Sclerosis, Relapsing Multiple Sclerosis
- Interventions
- No Intervention
- Other
- Lead sponsor
- TG Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 109
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Huntsville, Alabama + 98 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Datopotamab Deruxtecan, Pembrolizumab, Rilvegostomig
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 675 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 62
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 53 more
- Conditions
- Aging, Cognitive Change, Neurocognitive Disorders, Mild
- Interventions
- Contingent rtfMRI neurofeedback training, Non-contingent/sham rtfMRI neurofeedback training
- Behavioral
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma, Immature Teratoma, Malignant Teratoma, Mixed Germ Cell Tumor, Pineal Region Germ Cell Tumor, Pineal Region Immature Teratoma, Pineal Region Yolk Sac Tumor, Suprasellar Germ Cell Tumor
- Interventions
- Biospecimen Collection, Carboplatin, Etoposide, Filgrastim, Ifosfamide, Magnetic Resonance Imaging, Mesna, Pegfilgrastim, Peripheral Blood Stem Cell Transplantation, Questionnaire Administration, Radiation Therapy, Second-Look Surgery, Thiotepa
- Procedure · Drug · Biological + 2 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 3 Years to 29 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 152
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 120 more
- Conditions
- Generalized Anxiety Disorder
- Interventions
- Placebo, SEP-363856
- Other · Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 576 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 6
- States / cities
- Tucson, Arizona • Gainesville, Florida • Jacksonville, Florida + 3 more
- Conditions
- Obesity, Overweight
- Interventions
- Eloralintide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 59
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 52 more
- Conditions
- Geographic Atrophy
- Interventions
- SAR446597, Sham Comparator
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 28
- States / cities
- Peoria, Arizona • Scottsdale, Arizona • Beverly Hills, California + 22 more
- Conditions
- Transthyretin Amyloid Cardiomyopathy (ATTR CM)
- Interventions
- NNC6019-0001, Placebo (NNC6019-0001)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 63
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 49 more
- Conditions
- Advanced Solid Tumors, Lymphoma, Non-Hodgkin, Multiple Myeloma
- Interventions
- Abemaciclib (CLOSED TO ENROLLMENT), Atezolizumab and Talazoparib (CLOSED TO ENROLLMENT), Dabrafenib plus Trametinib, Fam-Trastuzumab Deruxtecan-Nxki (TDxD), Futibatinib, Nivolumab and Ipilimumab (CLOSED TO ENROLLMENT), Olaparib (CLOSED TO ENROLLMENT), Sunitinib (CLOSED TO ENROLLMENT), Talazoparib (CLOSED TO ENROLLMENT), Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT), Tucatinib plus Trastuzumab Subcutaneous (SC) (CLOSED TO ENROLLMENT), Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT)
- Drug
- Lead sponsor
- American Society of Clinical Oncology
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 4,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 174
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Auburn, California + 137 more
- Conditions
- Parkinson Disease
- Interventions
- HBI-002, Vehicle (placebo)
- Drug
- Lead sponsor
- Hillhurst Biopharmaceuticals, Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 8
- States / cities
- Fountain Valley, California • Gainesville, Florida • Boston, Massachusetts + 5 more